Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emisphere Technologies has announced that Novartis Pharma has launched a Phase I study in postmenopausal women to determine the safety and tolerability of oral PTH134, a combination of human PTH-1-34 and the absorption enhancer 5-CNAC using Emisphere's proprietary Eligen technology, for the treatment of postmenopausal osteoporosis.
Subscribe to our email newsletter
The study is designed to assess the bioavailability profile of increasing doses of PTH-1-34 combined with different amounts of 5-CNAC administered orally.
The trial is being conducted in Switzerland and is estimated to yield first interpretable results by the end of 2008.